Therapy News and Research

RSS

Women more likely to leave substance abuse treatment center after new tobacco-free policy

When a new tobacco-free policy was instituted at an Ohio women's substance abuse treatment center, both smokers and non-smokers were more likely to leave treatment early in the first few months after the policy change, a new study found.

7 May 2011

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

Experts from medical and patient communities call on national policymakers in the Asia-Pacific region to take urgent action against preventable strokes that strike millions of people with atrial fibrillation each year.

7 May 2011

ESC Heart Failure meeting offers strong scientific programme

This year the Heart Failure Congress 2011, organised by the Heart Failure Association of the European Society of Cardiology, offers a strong scientific programme featuring 11 late breaking trials and clinical updates, over 1000 original abstracts, 14 industry sponsored satellites and mini satellites and over 70 separate sessions.

7 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant.

7 May 2011

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis, according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore.

7 May 2011

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

Data presented as a Late Breaking Clinical Trial at Heart Rhythm 2011, the Heart Rhythm Society's 32nd Annual Scientific Sessions, shows the clinical benefit of cardiac resynchronization therapy versus conventional right-ventricle pacing in improving heart failure in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation.

From Medtronic 7 May 2011

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

sanofi-aventis and France’s Caisse des Dépôts announce today that the Caisse des Depots will acquire an interest in the Paris-based Biocitech life sciences technology park. Biocitech plays a key role in the development of the biotechnology industry in the department of Seine-Saint-Denis and the Greater Paris region.

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Abiomed presents PROTECT II study data in percutaneous coronary intervention at SCAI 2011

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced results from further 90 day clinical and economic analyses, based on data from the PROTECT II study.

7 May 2011

Novartis receives FDA approval for Afinitor to treat pancreatic neuroendocrine tumors

Yesterday, the U.S. Food and Drug Administration approved the Novartis drug Afinitor for the treatment of advanced pancreatic neuroendocrine tumors.

7 May 2011

Spherix effects 1-for-10 reverse stock split

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation, as amended, to effect a 1-for-10 reverse stock split of its common stock that will become effective at end of business today.

7 May 2011

Researchers establish new method to patch damaged heart with tissue-engineering platform

Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself.

7 May 2011

Inhalation therapy might halt and reverse progression of pulmonary arterial hypertension

Patients with pulmonary arterial hypertension struggle with severe symptoms, which include shortness of breath, exhaustion and a lack of vitality. Moreover, the disease, which is more common in women, often claims the patient's life within a few years of its development.

6 May 2011

BSX announces international launch and first implant of new cardiac devices

Boston Scientific Corporation today announced the launch and first implants of its ENERGEN and PUNCTUA cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators in Europe and other international markets.

6 May 2011

Boston Scientific provides new warranty program for CRT-D device to avoid phrenic nerve stimulation

Boston Scientific Corporation today announced that it is offering a new warranty program in the U.S. that covers its cardiac resynchronization therapy defibrillator devices and leads in the event of chronic phrenic nerve stimulation.

6 May 2011

CAMH presents new Microvolt T-wave Alternans testing data at Heart Rhythm Society meeting

Cambridge Heart, Inc. a developer of non-invasive diagnostic tests for cardiac disease, today announced that new data presented at the Heart Rhythm Society's 32nd Annual Scientific Sessions in San Francisco confirm the diagnostic value of Microvolt T-wave Alternans testing in identifying patients at risk of sudden cardiac arrest.

6 May 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

6 May 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

LRMC selects Allscripts as health information technology partner

Lakeway Regional Medical Center, a new physician/patient-focused acute care hospital in suburban Austin, has selected Allscripts as its health information technology partner to create a world-class care delivery infrastructure.

6 May 2011

Therapy News and Research

Women more likely to leave substance abuse treatment center after new tobacco-free policy

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

ESC Heart Failure meeting offers strong scientific programme

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Abiomed presents PROTECT II study data in percutaneous coronary intervention at SCAI 2011

Novartis receives FDA approval for Afinitor to treat pancreatic neuroendocrine tumors

Spherix effects 1-for-10 reverse stock split

Researchers establish new method to patch damaged heart with tissue-engineering platform

Inhalation therapy might halt and reverse progression of pulmonary arterial hypertension

BSX announces international launch and first implant of new cardiac devices

Boston Scientific provides new warranty program for CRT-D device to avoid phrenic nerve stimulation

CAMH presents new Microvolt T-wave Alternans testing data at Heart Rhythm Society meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Surgery reduces mortality risk of prostate cancer

LRMC selects Allscripts as health information technology partner

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News